miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs

Int J Mol Sci. 2022 Oct 14;23(20):12248. doi: 10.3390/ijms232012248.

Abstract

Gastrointestinal stromal tumors (GISTs) harboring mutations in the PDGFRA gene occur in only about 5-7% of patients. The most common PDGFRA mutation is exon 18 D842V, which is correlated with specific clinico-pathological features compared to the other PDGFRA mutated GISTs. Herein, we present a miRNA expression profile comparison of PDGFRA D842V mutant GISTs and PDGFRA with mutations other than D842V (non-D842V). miRNA expression profiling was carried out on 10 patients using a TLDA miRNA array. Then, miRNA expression was followed by bioinformatic analysis aimed at evaluating differential expression, pathway enrichment, and miRNA-mRNA networks. We highlighted 24 differentially expressed miRNAs between D842V and non-D842V GIST patients. Pathway enrichment analysis showed that deregulated miRNAs targeted genes that are mainly involved in the immune response pathways. The miRNA-mRNA networks highlighted a signature of miRNAs/mRNA that could explain the indolent behavior of the D842V mutated GIST. The results highlighted a different miRNA fingerprint in PDGFRA D842V GISTs compared to non-D842Vmutated patients, which could explain the different biological behavior of this GIST subset.

Keywords: D842V; GISTs; PDGFRA; gastrointestinal stromal tumors; miRNAs; microRNAs.

MeSH terms

  • Gastrointestinal Stromal Tumors* / genetics
  • Gastrointestinal Stromal Tumors* / pathology
  • Gastrointestinal Stromal Tumors* / therapy
  • Humans
  • Imatinib Mesylate
  • Immunologic Factors
  • Immunotherapy
  • MicroRNAs* / genetics
  • Mutation
  • Proto-Oncogene Proteins c-kit / genetics
  • RNA, Messenger
  • Receptor Protein-Tyrosine Kinases / genetics
  • Receptor, Platelet-Derived Growth Factor alpha / genetics

Substances

  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor alpha
  • MicroRNAs
  • Receptor Protein-Tyrosine Kinases
  • Immunologic Factors
  • RNA, Messenger
  • Proto-Oncogene Proteins c-kit

Grants and funding